Dosing Flexibility with PD-1 Inhibitors

This discussion reviews the dosing flexibility available for PD-1 inhibitors used in advanced gastric and gastroesophageal junction (GEJ) cancers. The discussion outlines how currently used agents offer validated dosing intervals that can be aligned with chemotherapy schedules to reduce additional clinic visits. Nivolumab may be administered every two or four weeks, while pembrolizumab can be given every three or six weeks; tislelizumab, as evaluated in first-line gastric and GEJ adenocarcinoma, is administered every three weeks. These options allow clinicians to tailor immunotherapy schedules based on treatment logistics, patient travel needs, and clinic capacity. The segment also notes that immune-related adverse events tend to occur early in treatment, a period when closer monitoring is often preferred, with longer dosing intervals becoming more feasible once patients transition off cytotoxic chemotherapy. Overall, the discussion highlights how having multiple PD-1 dosing schedules supports practical, patient-centered treatment planning for advanced gastric and GEJ cancers.